# Using Mitochondria to Treat Organ Damage After Blood Flow Problems

> This patent describes ways to use isolated mitochondria or special mitochondrial agents to treat or prevent damage to organs that happens when blood flow is cut off and then restored, like during a heart attack or surgery.

- **Patent:** US 12734194
- **Original title:** Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, medical_devices

## What it does

This patent focuses on compositions and methods for treating or preventing damage caused by ischemia-reperfusion injury (IRI). The core idea, as described in the abstract, is to use either isolated mitochondria or specific combined mitochondrial agents. These compositions are designed to be administered to a patient to protect tissues and organs from the harm that occurs when blood flow returns to an area that was previously deprived of oxygen. For example, after a heart attack, when blood flow is restored to the heart, the sudden rush of oxygen can cause further damage; this patent aims to provide a way to mitigate that secondary injury.

## What it does NOT cover

- Does not cover treatments for tissue damage not related to ischemia-reperfusion injury, such as direct trauma or infection.
- Does not cover the use of whole cells containing mitochondria, but specifically focuses on isolated mitochondria or combined mitochondrial agents.
- Does not cover therapies that do not involve mitochondrial components, even if they aim to treat ischemia-reperfusion injury.
- Does not cover the use of mitochondrial agents for enhancing athletic performance or general anti-aging purposes, as the focus is on therapeutic or prophylactic use for IRI.
- Does not cover methods of preventing IRI through surgical techniques or medication that do not involve mitochondrial compositions.

## The clever bit

The novelty lies in directly using isolated mitochondria or specific mitochondrial agents to intervene in the complex biological processes of ischemia-reperfusion injury. Instead of targeting symptoms, it aims to bolster the cell's energy powerhouses to better withstand and recover from stress.

## Real-world examples

1. Research into mitochondrial transplantation for cardiac repair
2. Clinical trials exploring mitochondrial therapies for stroke recovery
3. Development of drugs that enhance mitochondrial function to protect organs during surgery
4. Studies on using mitochondrial agents to improve outcomes in organ transplantation

## Why it matters

Ischemia-reperfusion injury is a significant problem in many medical conditions, including heart attacks, strokes, organ transplants, and major surgeries. This type of injury can lead to severe organ damage and even death. Developing new ways to prevent or treat IRI could greatly improve patient outcomes and expand the possibilities for complex medical procedures like organ transplantation.

## Frequently asked questions

### What does Using Mitochondria to Treat Organ Damage After Blood Flow Problems cover?

This patent describes ways to use isolated mitochondria or special mitochondrial agents to treat or prevent damage to organs that happens when blood flow is cut off and then restored, like during a heart attack or surgery.

### When does this patent expire?

This patent is expected to expire on September 15, 2046, when the invention enters the public domain.

### What problem does this patent solve?

Ischemia-reperfusion injury is a significant problem in many medical conditions, including heart attacks, strokes, organ transplants, and major surgeries. This type of injury can lead to severe organ damage and even death. Developing new ways to prevent or treat IRI could greatly improve patient outcomes and expand the possibilities for complex medical procedures like organ transplantation.

### What does this patent NOT cover?

Does not cover treatments for tissue damage not related to ischemia-reperfusion injury, such as direct trauma or infection.

**Full plain-English explainer:** https://patentbrief.org/patent/us/12734194/prophylactic-and-therapeutic-use-of-mitochondria-and-combined-mitochondrial

**Original patent:** https://patents.google.com/patent/US12734194

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._